Showing 2791-2800 of 3415 results for "".
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.
- FDA Approves Restylane Lyft for Chin Augmentation in Adultshttps://practicaldermatology.com/news/fda-approves-restylane-lyft-for-chin-augmentation-in-adults/2484326/Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Restylane® Lyft™ with Lidocaine for chin augmentation in adults over 21 with mild-to-moderate chin retrusion.
- BE HEARD: Bimekizumab Shows Sustained Relief in HS Symptoms Through 3 Yearshttps://practicaldermatology.com/news/be-heard-bimekizumab-shows-sustained-relief-in-hs-symptoms-through-3-years/2484274/Long-term data from the BE HEARD study showed BIMZELX® (bimekizumab-bkzx) was linked with sustained reductions in draining tunnels and clinically meaningful skin pain relief in patients with moderate-to-severe hidradenitis suppurativa (HS) through three years. <
- Topical Caffeine May Provide Hair Growth Benefit for Alopecia: Studyhttps://practicaldermatology.com/news/topical-caffeine-may-provide-hair-growth-benefit-for-alopecia-study/2484243/Topical caffeine may be a promising adjunct treatment for hair loss, according to a systematic review published in the Journal of Drugs in Dermatology. The analysis assessed original studies investigating caffeine’s effects on hair growth across multiple fo
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://practicaldermatology.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- FDA Approves Guselkumab for Children 6 and Older With PsOhttps://practicaldermatology.com/news/fda-approves-guselkumab-for-children-6-and-older-with-pso/2483604/The US Food and Drug Administration (FDA) has approved guselkumab (Tremfya®, Johnson & Johnson) for the treatment of children 6 and older, weighing at least 40 kg, with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), making it the
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the
- Analysis: Dupilumab-Related Adverse Events Less Common in Black Adults With ADhttps://practicaldermatology.com/news/analysis-dupilumab-related-adverse-events-less-common-in-black-adults-with-ad/2483504/A retrospective chart review in the Journal of Drugs in Dermatology yielded insights into dupilumab-associated adverse events (d-AEs) in Black and African American (AA) adults treated for atopic dermatitis (AD). The st